A Phase 1, Open-Label Study to Evaluate the Effect of Rifampin or Itraconazole on the Pharmacokinetics of GDC-0032 in Healthy Subjects

Trial Profile

A Phase 1, Open-Label Study to Evaluate the Effect of Rifampin or Itraconazole on the Pharmacokinetics of GDC-0032 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Taselisib (Primary) ; Itraconazole; Rifampicin
  • Indications Bacterial infections; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 02 Mar 2016 Study design changed from non-randomized to randomized as reported by ClinicalTrials.gov record.
    • 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 23 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top